PRACTICE guidelines recommend that patients with low risk PCa should be treated with AS. 1, 2 The purpose of AS is to reduce overtreatment and attendant morbidity without compromising the opportunity to cure lethal disease.
The exact criteria used to determine eligibility for AS vary importantly. For instance, in a systematic review on AS Dall'Era et al reported that in 7 major AS series eligibility criteria were used that differed in clinical stage, biopsy grade, PSA and biopsy core features. 3 Of the criteria used for AS the prognostic value of GrdGrp and stage are unambiguous 4, 5 and there has been considerable study of PSA level. 6 To date there has been little research on the prognostic value of biopsy cores.
The goal of our study was to determine the relationship between the number of positive biopsy cores and the oncologic risk. In particular we were interested in evaluating the widely used criterion that patients with more than 3 positive cores or more than 50% cancer involvement in any 1 core should be referred for immediate treatment. 3 
MATERIALS AND METHODS
After obtaining institutional review board approval we retrospectively collected data on 3,359 men who had GrdGrp 1 (Gleason score 3 þ 3 ¼ 6) disease on biopsy and PSA 10 ng/ml or less, and underwent RP at our institution between January 2000 and August 2016. While 86% of biopsies before RP were done elsewhere, the pathology results of these biopsies were reviewed at our institution prior to surgery.
We aimed to evaluate the relationship between the amount of cancer present on biopsy and the risk of adverse pathology findings at RP for low risk PCa. Adverse pathology was defined as GrdGrp 3 or greater (Gleason score 4 þ 3 ¼ 7 or greater), SVI or LNI. The amount of cancer was defined in 3 ways, including the number of positive biopsy cores, the total mm of cancer on biopsy and the maximum percent of cancer in any biopsy core. We excluded EPE and GrdGrp 2 (Gleason score 3 þ 4 ¼ 7) from our adverse pathology criteria as we had previously reported that the oncologic outcome remained favorable in cases of preoperatively low risk PCa which were up staged to EPE or upgraded to GrdGrp 2 following RP. 7 Using the Wilcoxon rank sum and Fisher exact tests we compared patient characteristics and the amount of cancer on biopsy between patients with and without adverse pathology findings at RP. To investigate whether the probability of adverse pathology increased significantly when there was a larger amount of cancer on biopsy, we plotted the probability of adverse pathology using LOWESS. As a sensitivity analysis we repeated all analyses using an alternate definition of adverse pathology that included GrdGrp 2 and EPE. We also performed a sensitivity analysis limited to patients who underwent biopsy or had all biopsy cores reviewed at our institution. All analyses were done with StataÒ, version 13.
RESULTS
The supplementary table (http://jurology.com/) lists patient characteristics. Adverse pathology at RP was present in 171 of the 3,359 patients (5.1%) who had low risk PCa on biopsy. Of these 171 cases 144 (4.3%) were upgraded to GrdGrp 3 or greater, 31 (0.9%) showed SVI, 15 (0.4%) showed LNI and 17 (0.5%) had 2 or more adverse features. Of note, 77% of the 3,359 patients underwent lymph node dissection since we believe that it improves the accuracy of PCa staging even in those at low risk.
The 171 patients with adverse pathology findings at RP were significantly older than the rest of the cohort (median age 62 years, IQR 56e66 vs 59, IQR 54e63, p <0.0001). These 171 patients had significantly higher PSA before RP than the rest of the cohort (median 5.8 ng/ml, IQR 4.5e7.1 vs 4.7, IQR 3.4e6.1, p <0.0001). The median number of positive cores in the whole cohort was 2 (IQR 1e3). The number of positive cores did not significantly differ between patients with vs without adverse pathology (p ¼ 0.7).
We tested whether there was a significant association between the amount of cancer on biopsy and the risk of adverse pathology results at RP. We found no evidence of an association between the number of positive cores (p ¼ 0.7), the total mm of cancer in the biopsy (p ¼ 0.6) or the maximum percent of cancer in any core (p >0.9, see table). Although we did not observe any significant associations, we wanted to explore the possibility of nonlinearity or discontinuities that would suggest a threshold for AS eligibility. Figure 1 shows the probability of adverse pathology findings in all patients based on the number of positive cores, the total mm of cancer on biopsy and the maximum percent of cancer in any biopsy core. There was no obvious evidence of a threshold effect.
On sensitivity analysis we repeated the analyses to include patients with GrdGrp 2 and EPE. Of the 3,359 patients 1,691 (50%) were found to have adverse pathology findings at RP based on this expanded definition. The number of positive biopsy cores, the total mm of cancer on biopsy, the maximum percent of cancer in any core, GrdGrp 2 and EPE were significantly associated with the risk of adverse pathology (all p <0.0001, see table). Figure 2 shows the risk of adverse pathology findings plotted against core features. Similar to our analyses that excluded GrdGrp 2 and EPE, there was no evidence to support commonly used thresholds such as 3 positive cores or maximum 50% core involvement and the risk of adverse pathology.
Furthermore, changes in risk were more moderate after these thresholds were reached.
We also performed the same analyses in the 1,721 patients who underwent biopsy or had all biopsy cores reviewed at our institution. Results were consistent with the main analysis and the corresponding figures looked similar but with larger CIs (supplementary figs. 1 and 2, http://jurology.com/).
DISCUSSION
AS is increasingly accepted as a safe approach to favorable risk PCa. In our study approximately 5% of the patients with GrdGrp 1 on biopsy and pretreatment PSA 10 ng/ml or less harbored adverse pathological features after RP.
Dall'Era et al detailed the long-term followup of 7 large series of AS and confirmed that AS could be confidently used to manage most indolent and nonlethal low risk PCa. 3 Of the 7 series the one from University of Toronto had the longest median followup of 6.4 years from the first biopsy. 8 Ten and 15-year cancer specific survival rates in this cohort were 98.1% and 94.3%, respectively. Of note, 25% of this cohort had intermediate risk PCa according to the D'Amico criteria. Mortality rates in this study were much lower than rates in patients with low risk PCa who were treated with watchful waiting and no option for radical intervention. 9 To our knowledge the ProtecT (Prostate Testing for Cancer and Treatment) trial is the only randomized trial to compare AS, RP and external beam radiotherapy for the treatment of clinically localized PCa. 10 It demonstrated that disease progression and metastatic evolution developed more frequently in the AS group. Therefore, the long-term safety of AS depends on the ability to select appropriate patients for AS and initiate treatment when needed.
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In the literature the probability of discontinuing AS for active treatment varied from 11% to 32% and depended on regular PSA followups, physical examination and rebiopsy. 3 Most patients discontinued AS within the first 3 years, probably because disease grade and extent was initially underestimated. Of men who are recommended for AS 20% to 40% were shown to have higher GrdGrp or cancer volume after enrolling in AS. 12, 13 Several investigators have extensively examined the rates of upgrading and up staging at RP. For example, Filippou et al reported a 46% rate of adverse pathology findings after delayed RP, including up staging, positive surgical margins or upgrading. 14 Ploussard et al found that even with a stringent 21-core biopsy protocol the rate of upgrading after RP in men eligible for AS was as high as 48%. 15 These results are concordant with the 50% of adverse pathology results that we found after RP when expanding the definition of adverse pathology to include GrdGrp 2 or greater and EPE.
Several studies have demonstrated how adverse pathological features influence the risk of BCR, including randomized trials revealing the benefit of adjuvant radiotherapy in men with adverse pathological features at RP. 16, 17 However, these trials included a heterogeneous cohort of patients without clear delineation of risk groups. We previously reported that adverse pathological features did not have the same clinical relevance depending on the preoperative risk. 7 For example, the 5-year BCR risk in patients with low risk PCa at the initial evaluation but with EPE at RP was 15% compared to 43% in the overall population with EPE. The risk of BCR is influenced not only by adverse pathological features but also substantially by pretreatment factors. When counseling a patient who is considering AS, the risk of adverse pathological features 7 Patients with EPE are a heterogeneous group and some investigators believe that tumors with capsular invasion and tumors with capsular penetration should be distinguished. 18 The level and/or extent of EPE also highly correlates to PCa grade. 19 Similarly, simply assigning a Gleason score of 7 may not reflect disease aggressiveness. With the advent of the GrdGrp system, which is based on the Gleason system but more clearly delineates GrdGrp 2 from 3, the prognosis was significantly worse for GrdGrp 3 than for GrdGrp 2, which showed recurrence-free progression after RP closer to that of GrdGrp 1. 20 Due to these reasons we only initially considered GrdGrp 3 or greater, SVI and LVI as clinical end points to assess the aggressive nature of the disease.
In the current study only patient age and PSA were significantly associated with the probability of adverse pathology findings. The number of positive cores, the total number of biopsy cores, the total length of cancer on biopsy and the maximum percent of cancer in any core were not predictive of adverse pathology at RP, although most AS protocols consider these criteria for inclusion. After expanding the definition of adverse pathology to include GrdGrp 2 or greater and EPE we found no evidence to support commonly used thresholds such as 3 positive cores or maximum 50% core involvement. Moreover, changes in risk were more moderate after these thresholds were reached, making them less clinically relevant. In the PRIAS study more than 2 positive cores on surveillance biopsy served as the criteria to switch to active treatment but this was not predictive of an unfavorable pathological outcome at RP. 21 In men who underwent RP due to more than 2 positive cores as the sole factor in progression the rate of adverse pathology, defined as GrdGrp 3 or greater, or pT3 or higher, was close to 50%. Half of these patients could have remained on AS.
Pathological features of positive cores have long been part of the criteria for many AS protocols. For instance, in the Johns Hopkins protocol men are eligible for AS only if they are at clinically low risk (PSA density less than 0.15 ng/ml/ml, cT1c and GrdGrp 1) and have fewer than 3 positive cores with no more than 50% cancer involvement in any core. 13 A similar approach was taken in the PRIAS study, although PSA less than 10 ng/ml was used in place of PSA density with no criterion for single core percent involvement. 22 We have not been able to find studies that clearly support the finding that a threshold number of cores or cancer involvement importantly increases the oncologic risk of GrdGrp 1 disease. Epstein criteria (PSA density less than 0.15 ng/ml/ml, GrdGrp 1 and 2 or fewer positive cores with cancer less than 3 mm on 1 core sample) were initially defined to predict insignificant cancer (GrdGrp 1 and less than 0.2 cm 3 ) on the RP specimen. 23 In a cohort of 472 men with screen detected PCa from the G€ oteborg screening trial 15-year PCa specific survival was 100% in those with very low risk prostate cancer according to Epstein criteria vs 94% in those with low risk prostate cancer, suggesting the predictive value of cores. 24 However, there was no statistical comparison and 1 of the 2 patients who died in the low risk group had what would currently have been graded as 3 þ 4 disease.
We believe that the criteria for AS were chosen conservatively based on educated guesswork when AS programs were first being developed and clinicians were understandably wary of including patients at higher risk. By exploring the performance of various criteria used to identify men with low risk disease in AS protocols Komisarenko et al found that selective criteria do not significantly improve short-term outcomes. 25 Consequently the criteria used at many institutions might be too restrictive and exclude many men who could benefit from AS.
Risk classification is clinically important to better select candidates for AS and adjust subsequent monitoring. There is still room for improvement in PCa staging and new techniques to increase the accuracy of initial evaluation are being investigated. Although the GrdGrp derived from prostate biopsy is upgraded after RP in up to 50% of men, MRI seems to be an effective method to exclude a higher GrdGrp. 26 The definitive results of the ASIST trial (ClinicalTrials.gov NCT01354171), which investigated whether multiparametric MRI could improve the selection of patients for AS at the time of confirmatory biopsy, should provide more information. Other approaches to evaluate new biomarkers include gene modification such as TMPRSS2:ERG fusion transcript in prostatic tissue or urine, 27 PCA3 in urine 28 and microRNAs. 29 The role of these markers is still under investigation.
A limitation of our retrospective study is that all specimens did not undergo a specific research review. Another limitation was that biopsies were not performed according to a uniform protocol. While a pathology review was done of all in-house or outside patient biopsy slides, most biopsies were performed elsewhere and may not have followed a uniform biopsy scheme. Furthermore, not all cores were submitted for review on each case. Other limitations include the absence of imaging and the selection of patients who were candidates for RP. These patients may not be representative of the overall population but fewer alternative therapies were available at the time of the study.
Adverse pathology after RP is not a perfect surrogate for oncologic outcomes. However, independently of pretreatment risk status it is an important predictive factor for BCR, progression to metastatic disease and death. 30 We believe that it should be considered in the prospective evaluation of AS protocols.
CONCLUSIONS
In this large, single center cohort approximately 5% of the patients with low risk prostate cancer harbored clinically relevant adverse pathology after RP. The association between core features and the probability of adverse pathology findings at RP is sensitive to the definition of adverse pathology. However, even with the expanded definition there was no evidence of a clinically important increase in risk for widely used AS criteria. There is little basis to exclude patients from AS based on threshold criteria such as the number of positive cores or maximum cancer involvement. 
EDITORIAL COMMENT
Pinpointing wolves dressed in sheep's clothes is an unmet need in patients on AS, requiring novel techniques or markers. The current study confirms that the number of positive cores or the maximum cancer involvement of biopsy cores is a poor predictor of adverse pathology. Indeed, more selective criteria do not translate into significantly improved short-term outcomes when considering the risk of grade reclassification or biochemical failure after treatment. This was shown in 1,085 men enrolled in an AS program at Princess Margaret Cancer Centre (reference 25 in article) who were assessed for entry eligibility into the PRIAS, Johns Hopkins, University of Miami, San Francisco, Memorial Sloan Kettering Cancer Center, Toronto-Sunnybrook and Royal Marsden protocols. No significant differences were noted between men who met Princess Margaret Cancer Centre criteria and those who were excluded from analysis based on more stringent criteria.
Whether MRI will become the ultimate tool to predict PCa upgrading remains to be proved. The results of ASIST led by Klotz et al were presented at the 2017 CUA (Canadian Urological Association) meeting. 1 The question raised was whether multiparametric MRI and targeted biopsy improved the detection of clinically significant cancer compared to systematic biopsy. Disappointingly no significant difference was observed in the rate of upgrading between confirmatory transrectal ultrasound biopsy and MRI guided targeted biopsy. 
REPLY BY AUTHORS
Although treatment options for localized prostate cancer have increased dramatically in the last decades with active surveillance and focal therapy added to the radical treatments, the accurate distinction between indolent and nonindolent disease has remained limited. Most of the debate has been focused on whether to diagnose prostate cancer but little progress has been made on the pretreatment risk evaluation. Clinicopathological criteria are poor predictors of the overall aggressiveness of the disease and using more selective criteria to identify men with low risk disease does not significantly improve short-term outcomes in active surveillance protocols (reference 25 in article). As demonstrated in our study, the criteria used at many institutions are probably too restrictive and exclude many men who might benefit from active surveillance.
To answer the dilemma faced when choosing between overtreatment and no treatment, urologists had high expectation for multiparametric MRI to predict the risk of Grade Group upgrading with a high negative predictive value. Preliminary results from the ASIST trials seem disappointing in this regard.
Consequently genomic characterization of localized prostate cancer might be the next step forward. ProlarisÒ, OncotypeDXÒ and genomic classifiers are available for biopsy tissue and were shown to provide prognostic information in men with clinically localized prostate cancer, in addition to conventional clinicopathological parameters. 1 In-depth analysis techniques in association with cell-free DNA from blood 2 could further help unmask wolves dressed in sheep's clothes.
